Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy.
about
Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patientsA Mini-Review for Cancer Immunotherapy: Molecular Understanding of PD-1/PD-L1 Pathway & Translational Blockade of Immune CheckpointsNovel technologies and emerging biomarkers for personalized cancer immunotherapyImmune Checkpoint Blockade: A New Paradigm in Treating Advanced CancerMetastatic castration-resistant prostate cancer: new therapies, novel combination strategies and implications for immunotherapyConcordance of preclinical and clinical pharmacology and toxicology of therapeutic monoclonal antibodies and fusion proteins: cell surface targetsCombining immunological and androgen-directed approaches: an emerging concept in prostate cancer immunotherapyAntibody-based immunotherapy for ovarian cancer: where are we at?Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlookIpilimumab: an anti-CTLA-4 antibody for metastatic melanomaRecent Advances in Immunotherapy in Metastatic NSCLCSuppressing T cell motility induced by anti-CTLA-4 monotherapy improves antitumor effects.Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort.Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic MelanomaEfficacy and safety of ipilimumab in patients with advanced melanoma and brain metastasesFour-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials.Breathing new life into immunotherapy: review of melanoma, lung and kidney cancerVISTA Regulates the Development of Protective Antitumor Immunity.Sub-lethal irradiation of human colorectal tumor cells imparts enhanced and sustained susceptibility to multiple death receptor signaling pathways.Model-based clinical pharmacology profiling of ipilimumab in patients with advanced melanomaThe immuno-oncology framework: Enabling a new era of cancer therapy.VISTA is an immune checkpoint molecule for human T cells.Big opportunities for small molecules in immuno-oncology.CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerationsPD-1 pathway inhibitors: the next generation of immunotherapy for advanced melanomaClinical Development of Immune Checkpoint Inhibitors.Past, present and future targets for immunotherapy in ovarian cancerRoles of the immune system in skin cancer.Phase I study of ipilimumab in phased combination with paclitaxel and carboplatin in Japanese patients with non-small-cell lung cancer.Immunotherapy treatments for small-cell lung cancer: past, present and future.Predicting analysis times in randomized clinical trials with cancer immunotherapyCharacteristics and management of immunerelated adverse effects associated with ipilimumab, a new immunotherapy for metastatic melanoma.Use of ipilimumab in the treatment of melanoma.Dabrafenib in metastatic melanoma: a monocentric 'real life' experience.Immunological markers and clinical outcome of advanced melanoma patients receiving ipilimumab plus fotemustine in the NIBIT-M1 study.Is there a role for immune checkpoint blockade with ipilimumab in prostate cancer?Mechanistic roles of epithelial and immune cell signaling during the development of colitis-associated cancer.Ipilimumab: A First-in-Class T-Cell Potentiator for Metastatic Melanoma.Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study.Ipilimumab (Anti-Ctla-4 Mab) in the treatment of metastatic melanoma: Effectiveness and toxicity management.
P2860
Q24598792-839F3D0C-F828-4A87-8DDD-29A05C857EABQ26738729-86992678-8EF6-4D95-996D-13995A173F05Q26770780-5066DB4E-68C6-4C83-B1FB-82F8FC3AA9F3Q26795509-56BA81B9-5872-42B7-8758-925C064919A5Q26825053-77D51028-D7D3-4A2C-BFF1-167719DFD7E5Q26830569-751478CB-3972-4C99-939C-8A7CF45AAEC4Q26851608-F98BB34B-5211-48D0-A22F-B529406AF76CQ27000514-F36ABD46-ECEF-431B-909C-9A5ED8E1ED10Q27004178-DF1857EE-1686-4AEF-A86B-E29CE5256A3EQ27005902-8901BE3A-A8F7-4782-845D-042F84678D9BQ28069323-2A6732C1-83E7-4EEE-940F-305E9DD9D487Q30525394-7563DE76-BDA9-4493-80EF-02F1C8D5FBB2Q30828178-306817E7-061C-4FB1-B8AE-F97EFD5DC970Q30890582-B5E93073-D693-4565-8F57-1430C4296EE6Q33620317-57C8012F-BB2A-4C3D-8169-5AC9DAA493E4Q33845393-85CDAC4B-3B80-4796-BD77-923D745A8506Q33862861-BF9C46E5-5B19-482A-B9D3-7E4D555C0ABAQ33978040-4939B744-E7CC-4DC3-9B4D-E7E193660428Q34184469-C2B4571B-7556-428E-838B-C845A9ECF54BQ34209549-B3B926F6-7C70-4A24-B227-848054213EBFQ34284462-2AF386A7-9532-4CCD-9CD0-7C3F198A5515Q34413221-5D4EAAEC-51AB-4DED-ADD9-C5E27AFF146AQ34487689-93ACBF64-13DE-43E6-A240-8C0A9405BBEEQ34667662-D5515C45-609F-49C4-A10A-C9C323BCAE78Q34667977-5BE1385A-E1EE-440E-B326-A29B4F5D7E0CQ34671498-6BE5729E-4D86-43AC-8F53-54F20000C356Q35034010-54EB8DE4-F106-4E0D-9427-F65256168AABQ35403714-19D24241-01FB-43E0-ABF3-3D74BAF0BD7DQ35817265-15293D42-5139-46E6-BCB0-BB305EFE1718Q35904003-8088A66D-64E4-4EE8-A92C-3C493D2817EDQ35910361-C0954AF8-E38B-478F-9481-C22867818233Q36283747-40F50845-0571-44DA-98FF-701A8F3E7819Q36571769-A46CF8F9-7C5A-4F79-B9C8-522C1D31A351Q36652790-66D1E1EB-4721-467F-900E-EB1D7B9640A4Q36711007-22E65F52-F4F8-47FA-B2FF-14BE923D36C6Q36804897-E83C5630-7B54-42AA-A207-B1A2DAD157D2Q36827259-A7BE758F-6519-42CD-899E-DACDA4BCFA04Q36879912-F5AF091F-567C-461B-B616-118547DC25A7Q36999978-2E192B09-D226-49BD-AB54-236236922D0FQ37131014-89EEB8D2-0C8E-4D01-A436-B8132498F023
P2860
Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy.
description
2010 nî lūn-bûn
@nan
2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
name
Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy.
@ast
Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy.
@en
Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy.
@nl
type
label
Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy.
@ast
Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy.
@en
Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy.
@nl
prefLabel
Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy.
@ast
Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy.
@en
Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy.
@nl
P2093
P1433
P1476
Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy.
@en
P2093
Alan Korman
David Berman
Kald Abdallah
Kevin Chin
Rachel Humphrey
Ramy Ibrahim
Renzo Canetta
Vafa Shahabi
P304
P356
10.1053/J.SEMINONCOL.2010.09.015
P577
2010-10-01T00:00:00Z